Luka Penezić
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luka Penezić has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Željko Kaštelan
Department of Urology, University Hospital Center Zagreb, Zagreb, Croatia
8 shared publicationsTvrtko Hudolin
Department of Urology, University Hospital Center Zagreb, Zagreb, Croatia
6 shared publicationsNikola Knežević
Department of Urology University Hospital Centre Zagreb Zagreb Croatia
5 shared publicationsHrvoje Saić
Department of Urology University Hospital Centre Zagreb Zagreb Croatia
4 shared publicationsTomislav Kuliš
Department of Urology, Zagreb University Hospital Center, Zagreb, Croatia; University of Zagreb School of Medicine, Zagreb, Croatia
4 shared publicationsToni Zekulić
Department of Urology, Zagreb University Hospital Center, Zagreb, Croatia
4 shared publications
Latest Publications
- 20 May 2024
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 24 (3) , 1-9
Inosine monophosphate dehydrogenase type 2 polymorphism IMPDH2 3757T>C (rs11706052) and 12-month evolution of the graft function in renal transplant recipients on mycophenolate-based immunosuppression
Variant allele at the inosine monophosphate dehydrogenase type 2 polymorphism IMPDH2 3757T>C has been associated with increased enzyme activity and reduced susceptibility to mycophenolic acid (MPA) in vitro. It has been suggested associated with an increased risk of acute rejection in renal transplant recipients on MPA-based immunosuppression, but not unambiguously. We assessed one-year evolution of the estimated glomerular filtration rate (eGFR) in transplanted variant allele carriers and wild-type subjects, while controlling for a number of demographic, pharmacogenetic, (co)morbidity, and treatment baseline and time-varying covariates. The eGFR slopes to day 28 (GMR = 1.01, 95% CI 0.93–1.09), and between days 28 and 365 (GMR = 1.01, 95% CI 0.99–1.02) were practically identical in 52 variant carriers and 202 wild-type controls. The estimates (95%CIs) remained within the limits of ±20% difference even after adjustment for a strong hypothetical effect of unmeasured confounders. Polymorphism IMPDH2 3757T>C does not affect the renal graft function over the 1st year after transplantation.
- 20 May 2024
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 24 (3) , 1-9
Inosine monophosphate dehydrogenase type 2 polymorphism IMPDH2 3757T>C (rs11706052) and 12-month evolution of the graft function in renal transplant recipients on mycophenolate-based immunosuppression
Variant allele at the inosine monophosphate dehydrogenase type 2 polymorphism IMPDH2 3757T>C has been associated with increased enzyme activity and reduced susceptibility to mycophenolic acid (MPA) in vitro. It has been suggested associated with an increased risk of acute rejection in renal transplant recipients on MPA-based immunosuppression, but not unambiguously. We assessed one-year evolution of the estimated glomerular filtration rate (eGFR) in transplanted variant allele carriers and wild-type subjects, while controlling for a number of demographic, pharmacogenetic, (co)morbidity, and treatment baseline and time-varying covariates. The eGFR slopes to day 28 (GMR = 1.01, 95% CI 0.93–1.09), and between days 28 and 365 (GMR = 1.01, 95% CI 0.99–1.02) were practically identical in 52 variant carriers and 202 wild-type controls. The estimates (95%CIs) remained within the limits of ±20% difference even after adjustment for a strong hypothetical effect of unmeasured confounders. Polymorphism IMPDH2 3757T>C does not affect the renal graft function over the 1st year after transplantation.
- 20 January 2024
- Published by Springer Nature in World Journal of Urology
- Vol. 42 (1) , 1-8
Robotic-assisted radical prostatectomy: a multicenter experience with the Senhance Surgical System
Purpose Robotic-assisted surgery for radical prostatectomy is becoming a standard treatment, and respective implementations are expanding. The Senhance Surgical System is a robotic system with existing but limited data on radical prostatectomy, including a lack of multicenter study experiences. The TRUST study aims to fill this gap and explores observations for radical prostatectomy with the Senhance Surgical System. Methods Between August 2019 and November 2022, 375 patients met inclusion criteria from two European sites. Patients’ surgical procedure times, data on conversion, malfunction, adverse events, and pain scores were registered and evaluated. Outcomes were calculated for both sides, combined as a total and compared between the initial (1st–150th case) and later (> 150th case) period. Results The median operating time was 190 min (IQR: 167.5–215.0) and the median docking time was 3 min (IQR: 2.0–5.0). Eighteen cases (4.8%) were converted to standard laparoscopy and two (0.5%) to open. Two perioperative (0.5%) and eleven postoperative adverse events (2.9%) occurred, mostly (83.3%) categorized as mild. Pain scores were reduced from an average of 3.4 (± 1.4) on the postoperative day to 0.9 (± 0.7) at discharge. Compared to our previous data and based on a comparison between our initial and later period, operating time seems to plateau. However, docking time, complication, and conversion rates were successfully reduced. Conclusion We demonstrate progressing safety and efficiency for robotic-assisted radical prostatectomy with the Senhance Surgical System.
- 20 January 2024
- Published by Springer Nature in World Journal of Urology
- Vol. 42 (1) , 1-8
Robotic-assisted radical prostatectomy: a multicenter experience with the Senhance Surgical System
Purpose Robotic-assisted surgery for radical prostatectomy is becoming a standard treatment, and respective implementations are expanding. The Senhance Surgical System is a robotic system with existing but limited data on radical prostatectomy, including a lack of multicenter study experiences. The TRUST study aims to fill this gap and explores observations for radical prostatectomy with the Senhance Surgical System. Methods Between August 2019 and November 2022, 375 patients met inclusion criteria from two European sites. Patients’ surgical procedure times, data on conversion, malfunction, adverse events, and pain scores were registered and evaluated. Outcomes were calculated for both sides, combined as a total and compared between the initial (1st–150th case) and later (> 150th case) period. Results The median operating time was 190 min (IQR: 167.5–215.0) and the median docking time was 3 min (IQR: 2.0–5.0). Eighteen cases (4.8%) were converted to standard laparoscopy and two (0.5%) to open. Two perioperative (0.5%) and eleven postoperative adverse events (2.9%) occurred, mostly (83.3%) categorized as mild. Pain scores were reduced from an average of 3.4 (± 1.4) on the postoperative day to 0.9 (± 0.7) at discharge. Compared to our previous data and based on a comparison between our initial and later period, operating time seems to plateau. However, docking time, complication, and conversion rates were successfully reduced. Conclusion We demonstrate progressing safety and efficiency for robotic-assisted radical prostatectomy with the Senhance Surgical System.
- Open Access
- 25 July 2023
- Published by Springer Nature in Research Square
Inosine monophosphate dehydrogenase type 2 polymorphism IMPDH2 3757T>C (rs11706052) and 12-month evolution of the graft function in renal transplant recipients on mycophenolate-based immunosuppression
Variant allele at the inosine monophosphate dehydrogenase type 2 polymorphism IMPDH2 3757T > C has been associated with increased enzyme activity and reduced susceptibility to mycophenolic acid (MPA) in vitro. It has been suggested associated with an increased risk of acute rejection in renal transplant recipients on MPA-based immunosuppression, but not unambiguously. We assessed one-year evolution of the estimated glomerular filtration rate (eGFR) in 52 variant carriers and 202 wild-type controls exposed to MPA. Adjusted for a range of demographic, pharmacogenetic, (co)morbidity, and treatment baseline and time-varying covariates, the eGFR slopes to day 28 (GMR = 1.01, 95%CI 0.93–1.09), and between days 28 and 365 (GMR = 1.01, 95%CI 0.99–1.02) were practically identical in variant carriers and wild-type controls. The estimates (95%CIs) remained within the limits of ±20% difference even after adjustment for a strong hypothetical effect of unmeasured confounders. Polymorphism IMPDH2 3757T > C does not affect the renal graft function over the 1st year after transplantation.
- 25 July 2023
- Published by Springer Nature in Research Square
Open AccessInosine monophosphate dehydrogenase type 2 polymorphism IMPDH2 3757T>C (rs11706052) and 12-month evolution of the graft function in renal transplant recipients on mycophenolate-based immunosuppression
Variant allele at the inosine monophosphate dehydrogenase type 2 polymorphism IMPDH2 3757T > C has been associated with increased enzyme activity and reduced susceptibility to mycophenolic acid (MPA) in vitro. It has been suggested associated with an increased risk of acute rejection in renal transplant recipients on MPA-based immunosuppression, but not unambiguously. We assessed one-year evolution of the estimated glomerular filtration rate (eGFR) in 52 variant carriers and 202 wild-type controls exposed to MPA. Adjusted for a range of demographic, pharmacogenetic, (co)morbidity, and treatment baseline and time-varying covariates, the eGFR slopes to day 28 (GMR = 1.01, 95%CI 0.93–1.09), and between days 28 and 365 (GMR = 1.01, 95%CI 0.99–1.02) were practically identical in variant carriers and wild-type controls. The estimates (95%CIs) remained within the limits of ±20% difference even after adjustment for a strong hypothetical effect of unmeasured confounders. Polymorphism IMPDH2 3757T > C does not affect the renal graft function over the 1st year after transplantation.
- 15 July 2023
- Published by Wiley in The International Journal of Medical Robotics and Computer Assisted Surgery
- Vol. 19 (6) , e2549
Senhance robotic radical prostatectomy: A single‐centre, 3‐year experience
Background: Senhance Surgical System is a novel robotic platform used in University Hospital Centre Zagreb since February 2019. In this study, we present our 3‐year experience with this platform.Patients and Methods: Data were prospectively collected for 200 patients who underwent extraperitoneal robotic radical prostatectomy (RRP) from May 2019 to March 2022.Results: The median age of the patients was 65 years, and the prostate‐specific antigen was 6.9 ng/mL. Clinically, most of the patients had T1c stage. The estimated blood loss was 250 mL, and there were 6 conversions to laparoscopic and 2 to open prostatectomy. There were 15 early postoperative complications, 11 Clavien‐Dindo classification grade I, 3 grade II and 1 grade IV. Functional outcomes in the first 150 patients: 140 patients (93.3%) had good urinary control. Thirteen patients underwent additional oncological treatment.Conclusion: RRP performed with the Senhance robotic platform is a feasible and safe procedure with good initial results.
- 15 July 2023
- Published by Wiley in The International Journal of Medical Robotics and Computer Assisted Surgery
- Vol. 19 (6) , e2549
Senhance robotic radical prostatectomy: A single‐centre, 3‐year experience
Background: Senhance Surgical System is a novel robotic platform used in University Hospital Centre Zagreb since February 2019. In this study, we present our 3‐year experience with this platform.Patients and Methods: Data were prospectively collected for 200 patients who underwent extraperitoneal robotic radical prostatectomy (RRP) from May 2019 to March 2022.Results: The median age of the patients was 65 years, and the prostate‐specific antigen was 6.9 ng/mL. Clinically, most of the patients had T1c stage. The estimated blood loss was 250 mL, and there were 6 conversions to laparoscopic and 2 to open prostatectomy. There were 15 early postoperative complications, 11 Clavien‐Dindo classification grade I, 3 grade II and 1 grade IV. Functional outcomes in the first 150 patients: 140 patients (93.3%) had good urinary control. Thirteen patients underwent additional oncological treatment.Conclusion: RRP performed with the Senhance robotic platform is a feasible and safe procedure with good initial results.
- Open Access
- 1 January 2023
- Published by Sestre Milosrdnice University Hospital Center (KBC Sestre milosrdnice) in Acta Clinica Croatica
- Vol. 62. (Supplement) , 60-66
Laparoscopic Adrenal-Sparing Surgery Case Series: Partial Adrenalectomy and Cyst Resection
The aim is to present our case series documenting indications, laparoscopic technique, surgical and endocrinologic outcomes of laparoscopic partial adrenalectomy. In the period from April 2011 until October 2021, we performed 39 procedures. The pat...
- 1 January 2023
- Published by Sestre Milosrdnice University Hospital Center (KBC Sestre milosrdnice) in Acta Clinica Croatica
- Vol. 62. (Supplement) , 60-66
Open AccessLaparoscopic Adrenal-Sparing Surgery Case Series: Partial Adrenalectomy and Cyst Resection
The aim is to present our case series documenting indications, laparoscopic technique, surgical and endocrinologic outcomes of laparoscopic partial adrenalectomy. In the period from April 2011 until October 2021, we performed 39 procedures. The pat...
- Open Access
- 16 November 2022
- Published by Springer Nature in Research Square
Loss of function ABCG2 c.421C>A (rs2231142) polymorphism increases steady-state exposure to mycophenolic acid in stable renal transplant recipients: exploratory matched cohort study
Introduction. Polymorphism ABCG2 c.421C > A (rs2231142) results in a reduced activity of the important drug efflux transporter breast cancer resistance protein (BCRP/ABCG2). One study suggested that it may affect enterohepatic recirculation of mycophenolic acid (MPA). We evaluated the effect rs2231142 on steady-state exposure to MPA in renal transplant recipients. Methods. Consecutive, stable adult (age ≥ 16 years) renal transplant recipients on standard MPA-based immunosuppressant protocols (N = 68, 43 co-treated with cyclosporine, 25 with tacrolimus) underwent routine therapeutic drug monitoring after a week of initial treatment, and were genotyped for ABCG2 c.421C > A and 11 polymorphisms in genes encoding enzymes and transporters implicated in MPA pharmacokinetics. ABCG2 c.421C > A variant vs. wild-type (wt) patients were matched in respect to demographic, biopharmaceutic and genetic variables (full optimal combined with exact matching) and compared for dose-adjusted steady-state MPA pharmacokinetics (frequentist and Bayes [skeptical neutral prior] estimates of geometric means ratios, GMR). Results. Raw data (12 variant vs. 56 wt patients) indicated by around 40% higher total exposure (frequentist GMR = 1.45, 95%CI 1.10–1.91; Bayes = 1.38, 95%CrI 1.07–1.81) and by around 30% lower total body clearance (frequentist GMR = 0.66, 0.58–0.90; Bayes = 0.71, 0.53–0.95) in variant carriers than in wt controls. The estimates were similar in matched data (11 variant vs. 43 wt patients): exposure GMR = 1.41 (1.11–1.79) frequentist, 1.39 (1.15–1.81) Bayes, with 90.7% and 85.5% probability of GMR > 1.20, respectively; clearance GMR = 0.73 (0.58–0.93) frequentist, 0.71 (0.54–0.95) Bayes. Sensitivity analysis indicated high unsusceptibility of the estimates to unmeasured confounding. Conclusions. Loss-off-function polymorphism ABCG2 c.421C > A increases steady-state exposure to MPA in stable renal transplant patients.
- 16 November 2022
- Published by Springer Nature in Research Square
Open AccessLoss of function ABCG2 c.421C>A (rs2231142) polymorphism increases steady-state exposure to mycophenolic acid in stable renal transplant recipients: exploratory matched cohort study
Introduction. Polymorphism ABCG2 c.421C > A (rs2231142) results in a reduced activity of the important drug efflux transporter breast cancer resistance protein (BCRP/ABCG2). One study suggested that it may affect enterohepatic recirculation of mycophenolic acid (MPA). We evaluated the effect rs2231142 on steady-state exposure to MPA in renal transplant recipients. Methods. Consecutive, stable adult (age ≥ 16 years) renal transplant recipients on standard MPA-based immunosuppressant protocols (N = 68, 43 co-treated with cyclosporine, 25 with tacrolimus) underwent routine therapeutic drug monitoring after a week of initial treatment, and were genotyped for ABCG2 c.421C > A and 11 polymorphisms in genes encoding enzymes and transporters implicated in MPA pharmacokinetics. ABCG2 c.421C > A variant vs. wild-type (wt) patients were matched in respect to demographic, biopharmaceutic and genetic variables (full optimal combined with exact matching) and compared for dose-adjusted steady-state MPA pharmacokinetics (frequentist and Bayes [skeptical neutral prior] estimates of geometric means ratios, GMR). Results. Raw data (12 variant vs. 56 wt patients) indicated by around 40% higher total exposure (frequentist GMR = 1.45, 95%CI 1.10–1.91; Bayes = 1.38, 95%CrI 1.07–1.81) and by around 30% lower total body clearance (frequentist GMR = 0.66, 0.58–0.90; Bayes = 0.71, 0.53–0.95) in variant carriers than in wt controls. The estimates were similar in matched data (11 variant vs. 43 wt patients): exposure GMR = 1.41 (1.11–1.79) frequentist, 1.39 (1.15–1.81) Bayes, with 90.7% and 85.5% probability of GMR > 1.20, respectively; clearance GMR = 0.73 (0.58–0.93) frequentist, 0.71 (0.54–0.95) Bayes. Sensitivity analysis indicated high unsusceptibility of the estimates to unmeasured confounding. Conclusions. Loss-off-function polymorphism ABCG2 c.421C > A increases steady-state exposure to MPA in stable renal transplant patients.
- Open Access
- 1 April 2022
- Published by Croatian Medical Journals in Croatian Medical Journal
- Vol. 63 (2) , 197-201
Senhance robot-assisted adrenalectomy: a case series
We present a case series of 12 consecutive robot-assisted adrenalectomies performed from May 2019 to March 2020 by a single surgeon experienced in laparoscopy using the novel Senhance robotic system. Eleven patients had primary aldosteronism due to an ...
- 1 April 2022
- Published by Croatian Medical Journals in Croatian Medical Journal
- Vol. 63 (2) , 197-201
Open AccessSenhance robot-assisted adrenalectomy: a case series
We present a case series of 12 consecutive robot-assisted adrenalectomies performed from May 2019 to March 2020 by a single surgeon experienced in laparoscopy using the novel Senhance robotic system. Eleven patients had primary aldosteronism due to an ...
- 9 November 2021
- Published by Springer Nature in International Cancer Conference Journal
- Vol. 11 (1) , 96
Correction to: Letter to the editor on “Initial experience of laparoscopic radical nephrectomy using the Senhance® robotic system for renal cell carcinoma”
[This corrects the article DOI: 10.1007/s13691-021-00494-y.].
- 9 November 2021
- Published by Springer Nature in International Cancer Conference Journal
- Vol. 11 (1) , 96
Correction to: Letter to the editor on “Initial experience of laparoscopic radical nephrectomy using the Senhance® robotic system for renal cell carcinoma”
[This corrects the article DOI: 10.1007/s13691-021-00494-y.].
- 18 October 2021
- Published by Wiley in The International Journal of Medical Robotics and Computer Assisted Surgery
- Vol. 18 (1) , e2344
Comparison of extraperitoneal laparoscopic and extraperitoneal Senhance radical prostatectomy
Background: Senhance is novel robotic platform which can be used to perform radical prostatectomy (RP). We compare our results of robotic RP to similar patients operated with laparoscopic technique.Patients and methods: A prospective study of 61 patients operated laparoscopically and 107 patients operated using the Senhance robotic system. We have analysed operative and postoperative results in both groups.Results: There was no difference in the operative time, estimated blood loss, positive surgical margins, length of hospitalisation and catheterisation. There were 4 (6.5%) Clavien–Dindo grade I complications, and 5 (8.1%) late complications in laparoscopy. There were 6 (5.6%) Clavien–Dindo grade I, 3 (2.8%) grade II, 1 (0.9%) grade IV complications and 2 (1.9%) late complications in robotic group.Conclusion: Senhance robot‐assisted RP is safe, feasible and offers good and comparable functional and oncological outcomes to laparoscopy. The transition to robotic surgery with a relatively fast learning curve can be done effectively for surgeons with previous laparoscopic experience.
- 18 October 2021
- Published by Wiley in The International Journal of Medical Robotics and Computer Assisted Surgery
- Vol. 18 (1) , e2344
Comparison of extraperitoneal laparoscopic and extraperitoneal Senhance radical prostatectomy
Background: Senhance is novel robotic platform which can be used to perform radical prostatectomy (RP). We compare our results of robotic RP to similar patients operated with laparoscopic technique.Patients and methods: A prospective study of 61 patients operated laparoscopically and 107 patients operated using the Senhance robotic system. We have analysed operative and postoperative results in both groups.Results: There was no difference in the operative time, estimated blood loss, positive surgical margins, length of hospitalisation and catheterisation. There were 4 (6.5%) Clavien–Dindo grade I complications, and 5 (8.1%) late complications in laparoscopy. There were 6 (5.6%) Clavien–Dindo grade I, 3 (2.8%) grade II, 1 (0.9%) grade IV complications and 2 (1.9%) late complications in robotic group.Conclusion: Senhance robot‐assisted RP is safe, feasible and offers good and comparable functional and oncological outcomes to laparoscopy. The transition to robotic surgery with a relatively fast learning curve can be done effectively for surgeons with previous laparoscopic experience.
- 15 June 2021
- Published by Springer Nature in International Cancer Conference Journal
- Vol. 10 (4) , 346-347
Letter to the editor on "Initial experience of laparoscopic radical nephrectomy using the Senhance® robotic system for renal cell carcinoma"
- 15 June 2021
- Published by Springer Nature in International Cancer Conference Journal
- Vol. 10 (4) , 346-347
Letter to the editor on "Initial experience of laparoscopic radical nephrectomy using the Senhance® robotic system for renal cell carcinoma"